Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03518801 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol and Prolonged Exposure
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT03518801: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT03518801 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 136 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03518801, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The trial will include a randomized control trial to evaluate the efficacy of using Cannabidiol (CBD), a non-intoxicating cannabinoid, as an adjunctive to Prolonged Exposure therapy (PE). The trial will compare PE + CBD to PE + placebo in a sample of 136 military Veterans with PTSD at the VA San Diego Medical Center. The study represents the logical and innovative next step for augmenting existing treatments and developing novel pharmacotherapy for PTSD. Findings from the proposed RCT will inform clinical practice and policy by investigating whether administration of CBD in the context of PE therapy will improve treatment outcomes for military Veterans with PTSD.
Interventions
- DRUG Cannabidiol
- DRUG placebo
- BEHAVIORAL Prolonged Exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03518801
The ClinicalTrials.gov registry entry for NCT03518801 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cannabidiol is the first listed.
NCT03518801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03518801 about?
NCT03518801 is a clinical study titled "Cannabidiol and Prolonged Exposure". The trial will include a randomized control trial to evaluate the efficacy of using Cannabidiol (CBD), a non-intoxicating cannabinoid, as an adjunctive to Prolonged Exposure therapy (PE). The trial will compare PE + CBD to PE + placebo in a sample of 136 military Veterans with PTSD at the VA San Die...
What is the current status of trial NCT03518801?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2019-10-01. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT03518801?
The interventions under investigation include: Cannabidiol (DRUG), placebo (DRUG), Prolonged Exposure (BEHAVIORAL).
Who is sponsoring clinical trial NCT03518801?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.